博尔泰力(苦参素)治疗慢性乙型肝炎临床疗效观察  

A study of Marine (Oxymatrine) treatment chronic hepatitis B

作　　者：李葳[1] 马丽娜[1] 刘娅[1] 丁向春[1] 杨岩[1] 张平[1] 李玉芳[1] 张栩[1] 王煜[1] 

机构地区：[1]宁夏医学院附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2001年第12期715-717,共3页Ningxia Medical Journal

摘　　要：目的　探讨博尔泰力治疗慢性乙肝的合理剂量及远期疗效。方法　博尔泰力注射液Ⅰ组 (4 0 0mg)治疗慢性乙肝 74例 ,Ⅱ组 (6 0 0mg)治疗慢性乙肝 90例 ,与α -干扰素 (IFN -α)治疗的慢性乙肝 75例比较并随访 1年。结果博尔泰力Ⅰ组HBeAg阴转率 32 .4% ,HBV -DNA阴转率 37.8% ;Ⅱ组分别为 36 .7%和 40 .0 % ;IFN -α组分别为 41.3%和 44 .0 % (P >0 .0 5 )。 1年后随访博尔泰力Ⅰ组二项阴转率分别为 36 .1%和 2 7.9% ;Ⅱ组二项阴转率分别为 38.5 %和 2 9.5 % ;IFN -α组二项阴转率分别为 42 .4%和 42 .4% (P >0 .0 5 )。结论　博尔泰力注射液治疗Ⅰ、Ⅱ组对慢性乙肝远期疗效均良好 ,可与干扰素媲美 。Objectives To study Marine (Oxymatrine) treatment chronic hepatitis B of appropriate does and the long-term efficacy.Methods Marine (Oxymatrine) Ⅰgroup (400mg) treatment 74 patients with chronic hepatitis B, Ⅱgroup (600mg) treatment 90 patients with chronic hepatitis B , compare with α-IFN treatment 75 patients with chronic hepatitis B, while visiting one year.Results HBeAg loss and HBV-DNA loss of Marine (Oxymatrine) I group (400mg) was 32.4% and 37.8%, Ⅱgroup (600mg) was 36.7% and 40.0%; α-IFN group was 41.3% and 44.0% (p>0.05). After visiting one year, HBeAg loss and HBV-DNA loss of Marine (Oxymatrine) I group (400mg) was 36.1% and 27.9%; Ⅱgroup (600mg) was 38.5% and 29.5%;α-IFN group was 42.4%and 42.4%(p>0.05).Conclusions To two groups patients with chronic hepatitis B, Marine (Oxymatrine) treatment were better and didnt find out side-effection. So Marine (Oxymatrine) treatment chronic hepatitis B is as good asα-IFN,is a helpful kind of durg treatment chronic hepatitis B.

关 键 词：乙型肝炎 博尔泰力 治疗 

分 类 号：R512.62[医药卫生—内科学]